The DDW Conference:
Digestive Disease Week 2025 hosts medical professionals and researchers from every corner of gastroenterology and the world. At the biggest USA-based GI conference, Evinature co-founders presented CurQD® to hundreds of fascinated GI experts, pharmaceutical companies, and biotech enthusiasts alike with two posters displaying the latest and greatest CurQD® has to offer.
Held from May 3rd to 6th in sunny San Diego, Evinature’s presence is an exciting maneuver that positions CurQD® not just as the famed science-backed nutraceutical it is, but a potential answer to insurance companies and patient co-pays alike.
Poster 1: Cost-Effectiveness of CurQD® for Ulcerative Colitis
A recent study co-authored by Professor Henit Yanai (Rabin Medical Center, Israel) and Dr. David Rubin (University of Chicago) investigated the cost-effectiveness of CurQD® to treat ulcerative colitis compared to other advanced therapies in IBD. This study determined that CurQD® positioned itself as a significant add-on therapy that is clinically effective and reduces costs to the patients.
Poster 2: Retrospective Crohn’s Disease Study
In a presentation that was given earlier this year, Co-Founders Nir Salomon and Professor Shomron Ben-Horin displayed a clinical study wherein active Crohn’s Disease patients took CurQD® and were monitored before, during, and after treatment induction, with results testifying to the restorative potential of CurQD® in such medical cases. These findings confirm that CurQD® is effective not only for Ulcerative Colitis but also for Crohn’s Disease patients.
Photo credit: Aaron Blocker, Instagram IBD Patient Advocate and Warrior (@aaronblocker_)
Behind the Scenes:
Conferences aren’t just a crossroads for researchers, but the businessmen who put their money where their mouth is to invest real, science-backed solutions. DDW provided a tangible space for our Co-Founders to meet and hold productive conversations with high-ranking pharma reps, prominent gastroenterology science leaders and GI groups. These engagements reinforced CurQD®’s growing reputation as a clinically proven, economically viable nutraceutical protocol for IBD treatment while showing off its cost-benefit potential to help patients save and make gut healthcare affordable.
Looking Ahead:
Our presence at DDW 2025 marks a pivotal moment in Evinature’s journey—underscoring our commitment to scientific excellence and our mission to deliver accessible, effective treatments for patients with Ulcerative Colitis and Crohn’s Disease.
Stay tuned for further updates as we continue to expand CurQD®’s reach through clinical partnerships and global recognition.
Summer Pitocchelli-Schwartzman
